Our key Figures
 | 22,000 employeesin 149 countries, including 5,000 in France. |
 | 98% of Servier drugsactive principles are synthesized in its own plant in Bolbec-Baclair in France. |
 | 100 Million patientstreated daily with Servier medicinal products and generics. |
| | 5 major R&D areascardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes. |
 | 33 drug candidatesin research and development, including 23 new molecular entities. |
 | 15 international centers of clinical developmentand 3 research centers. |
| | 16 chemical and pharmaceutical production sitesproducing chemicals and pharmaceuticals worldwide. |
 | €4,2 billion euros in revenuecomprising €2.9 billion for branded drugs and €1.3 billion for generics. |
 | 25 % of turnover from Servier drugs is invested in R&Dexcluding generics. |
 | No. 1 independant french pharmaceutical companyno. 33 in the world; 3 research centres including 2 in France. |
 | No.1 in cardiology in Franceno. 2 in Europe, No. 5 in the world. |
 |
2nd leading preferred partner for research centers conducting clinical trialsAccording to CenterWatch rankings from March 2017, based on a total of 23 pharmaceutical companies |
 | Servier earned the highest score of A3++As in previous years, this high score represents excellence in honoring financial commitments. |
 | Participation reached 36,6% of the trade balance surplus in FranceIn pharmaceuticals and fine chemicals, amouting to €1.4 billion. |